Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)

Inclusion Criteria: * Patients with relapsed or refractory AML for which no standard therapies are anticipated to result in durable remission * Newly diagnosed Acute Myeloid Leukemia who are not considered suitable for other treatments. Exclusion Criteria: * Administration of anticancer agents (other than hydroxyurea) within 2 weeks prior to first dose of study drug, and administration of hydroxyurea within 24 hours prior to first dose of study drug * Participation in any other trial with an investigational product within the previous 30 days. * Uncontrolled intercurrent illness including, but not limited to, active infection, symptomatic congestive heart failure, cardiac arrhythmia or psychiatric illness/social situations